GSA CAPITAL PARTNERS LLP

Position in ALLO — Allogene Therapeutics, Inc.

CIK 1362033 LONDON, X0

Position in ALLO

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$370,201

-$470,976 QoQ

Shares Held

151,722

-75.3% QoQ

Ownership

0.044%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2020

14 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $100,711,343 across 163 Biotechnology names. ALLO ranks #87 (0.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$370,201	151,722	-75.3%	Shares	Sole	2026-05-08
2025-12-31	$841,177	613,998	+235.7%	Shares	Sole	2026-02-06
2025-09-30	$226,769	182,879	-62.8%	Shares	Sole	2025-11-07
2025-06-30	$556,096	492,121	+1.7%	Shares	Sole	2025-07-22
2025-03-31	$706,301	483,768	-42.1%	Shares	Sole	2025-05-08
2024-06-30	$1,946,346	835,342	+3971.3%	Shares	Sole	2024-08-15
2023-12-31	$65,862	20,518	-83.8%	Shares	Sole	2024-02-16
2023-09-30	$401,994	126,812	-49.6%	Shares	Sole	2023-11-15
2022-12-31	$1,581,205	251,384	+689.4%	Shares	Sole	2023-02-13
2022-09-30	$343,936	31,846	-78.6%	Shares	Sole	2022-11-14
2022-03-31	$1,355,604	148,804	+29.6%	Shares	Sole	2022-05-11
2021-12-31	$1,713,039	114,815	+723.0%	Shares	Sole	2022-02-14
2021-06-30	$363,842	13,951	+23.8%	Shares	Sole	2021-08-05
2020-12-31	$284,530	11,273	—	Shares	Sole	2021-02-03
No filing history on record for this holder in this stock.